Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics. The company's lead candidate includes ACR-368. Acrivon Therapeutics Inc. is based in WATERTOWN, Mass.
Info & Links
CEO
Peter Blume-Jensen
Headquarters
480 ARSENAL WAY, SUITE 100 WATERTOWN, MA 02472, UNITED STATES
Acrivon Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
57.22M
Enterprise Value
17.40M
Enterprise Value/EBITDA(ttm)
-0.19
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
0.92
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-47.95%
Return on Invested Capital(ttm)
-48.28%
Return on Assets(ttm)
-43.73%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-91.97M
Net Income Available to Common(ttm)
-80.56M
Diluted EPS(ttm)
-2.70
Share Statistics
Beta (5Y Monthly)
0.77
52-Week Change
-82.40%
S&P 500 52-Week Change
5.42%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
31.35M
Dividend Yield
0.00%
Float4
28.49M
% Held by Insiders
8.50%
% Held by Institutions
71.62%
Balance Sheet
Total Cash(mrq)
179.48M
Total Cash Per Share(mrq)
5.72
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
10.55%
Quick Ratio(mrq)
12.75%
Book Value Per Share(mrq)
5.66
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.94
Free Cash Flow(ytd)
-68.44M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.